Erratum: Safety and activity of varlilumab, a novel and first-in-class agonist anti-cd27 antibody, in patients with advanced solid tumors(Journal of Clinical Oncology (2017) 35:18(JCO2016701508) DOI: 10.1200/JCO.2016.70.1508);Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 35, Issue 18, 2017, Pages 2028-2036

  Burris, Howard A ^a   Infante, Jeffrey R ^a   Ansell, Stephen M ^b   Nemunaitis, John J ^c   Weiss, Geoffrey R ^d   Villalobos, Victor M ^e   Sikic, Branimir I ^e   Taylor, Matthew H ^f   Northfelt, Donald W ^g   Carson, William E ^h   Hawthorne, Thomas R ⁱ   Davis, Thomas A ⁱ   Yellin, Michael J ⁱ   Keler, Tibor ⁱ   Bullock, Timothy ^d  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c Mary Crowley Cancer Research Centers   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e STANFORD CANCER INSTITUTE   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g MAYO CLINIC   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ Celldex Therapeutics Inc   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; VARLILUMAB; ANTINEOPLASTIC AGENT; CD27 ANTIGEN; CYTOKINE; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; ASTHMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHILL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELIMINATION HALF-LIFE; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEVER; HEADACHE; HUMAN; HYPERTENSION; HYPONATREMIA; INSOMNIA; KIDNEY CARCINOMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL EDEMA; PHARMACODYNAMICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; REGULATORY T LYMPHOCYTE; SIDE EFFECT; SINGLE DRUG DOSE; TUMOR VOLUME; UPREGULATION; VOMITING; ADENOCARCINOMA; ADULT; AGED; AGONISTS; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; IMMUNOLOGY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROSTATIC NEOPLASMS; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD27; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; COLORECTAL NEOPLASMS; CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 85021749676     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.18.02262     Document Type: Erratum

References (26)

1. Postow MA, Callahan MK, Wolchok JD: Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974-1982, 2015
2. Hendriks J, Xiao Y, Borst J: CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J Exp Med 198:1369-1380, 2003
3. Hendriks J, Gravestein LA, Tesselaar K, et al: CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 1: 433-440, 2000
4. Agematsu K, Kobata T, Yang FC, et al: CD27/CD70 interaction directly drives B cell IgG and IgM synthesis. Eur J Immunol 25:2825-2829, 1995
5. Kobata T, Jacquot S, Kozlowski S, et al: CD27-CD70 interactions regulate B-cell activation by T cells. Proc Natl Acad Sci USA 92:11249-11253, 1995
6. Agematsu K, Nagumo H, Oguchi Y, et al: Generation of plasma cells from peripheral blood memory B cells: Synergistic effect of interleukin-10 and CD27/CD70 interaction. Blood 91:173-180, 1998
7. + peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 188:1679-1689, 1998
8. Yang FC, Agematsu K, Nakazawa T, et al: CD27/CD70 interaction directly induces natural killer cell killing activity. Immunology 88:289-293, 1996
9. Nishikawa H, Sakaguchi S: Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 27:1-7, 2014
10. Claus C, Riether C, Schürch C, et al: CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res 72: 3664-3676, 2012
11. Vitale LA, He LZ, Thomas LJ, et al: Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res 18:3812-3821, 2012
12. He LZ, Prostak N, Thomas LJ, et al: Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol 191:4174-4183, 2013
13. Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997
14. Korman A, Yellin M, Keler T: Tumor immunotherapy: Preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs 6: 582-591, 2005
15. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
16. + T-cell responses to a multipeptide melanoma vaccine: Outcome of a multicenter randomized trial. Clin Cancer Res 15: 7036-7044, 2009
17. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, et al: Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclo-phosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 29: 2924-2932, 2011
18. Alidzanovic L, Starlinger P, Schauer D, et al: The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance. Oncotarget 7:57197-57212, 2016
19. Friedman CF, Proverbs-Singh TA, Postow MA: Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncol 2:1346-1353, 2016
20. Ramakrishna V, Sundarapandiyan K, Zhao B, et al: Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab. J Immunother Cancer 3:37, 2015
21. + effector T cell pool. J Immunol 191: 3025-3036, 2013
22. Sznol M, Hodi FS, Margolin K, et al: Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol 26, 2008 (suppl 15S, abstr 3007)
23. Curti BD, Kovacsovics-Bankowski M, Morris N, et al: OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 73: 7189-7198, 2013
24. Rüter J, Antonia SJ, Burris HA, et al: Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther 10:983-993, 2010
25. Drabick JJ, Schell TD: Poking CD40 for cancer therapy, another example of the Goldilocks effect. Cancer Biol Ther 10:994-996, 2010
26. He L-Z, Thomas LJ, Testa J, et al: Combination therapies augment the anti-tumor activity of agonist CD27 mAb in human CD27 transgenic mouse models. J Immunother Cancer 1:P76, 2013